Page 2 - Ellen Chiniara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

WATERTOWN, Mass., Jan. 04, 2023 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein... | January 4, 2023

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio  Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities December 12, ...

12 december 2020 kl 13:59 Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca's broad-based revenue and the company will further globalise Alexion's portfolio Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the d...